{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Fatigue (Grade 1, 2)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Lymphopenia (Grade 1-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Thrombocytopenia (Grade 1-3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Leukopenia (Grade 1-3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Anemia (Grade 1-3)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"NCI CTCAE version 3.0 was used to assess Adverse Events (AE) Grade 1=Mild AE Grade 2=Moderate AE Grade 3=Severe AE Grade 4=Life-threatening or disabling AE","groups":[{"description":"Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.\n\nvorinostat: Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.\n\nCorrelative studies: Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at C2D1 (≈3 mos.), C3D1 (≈4 mos.), C5D1 (≈6 mos.),C7D1 (≈8 mos.), and off study (ideally at ≈12 mos.)","id":"OG000","title":"Vorinostat (SAHA)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation","type":"PRIMARY","unitOfMeasure":"patients"}